Últimas noticias sobre CEL-SCI (AMEX:CVM) Bolsa

CEL-SCI

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Urban Outfitters

ATCH

BTOG

DGLY

KDLY

LTRY

LUMN

MANU

NINE

NVTS

SEDG

SNOW

UPXI

URBN

VSTE

VTAK

WHLR

Longevity Health Holdings, Inc. - Common Stock

XAGE

Urban Outfitters sube tras superar expectativas de beneficios; otras acciones como Navitas y Snowflake también destacan en el premercado.

Acciones de Urban Outfitters (URBN) se disparan un 18%; Aquí están 20 acciones que se mueven en el premercado

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGMH

ANTE

ARBE

ARLO

ATXI

Bakkt Holdings, Inc. Class A Common Stock

BKKT

FINV

GNPX

GRAB

HNRG

HROW

HYPR

KTCC

VRPX

VSTM

Las acciones de Harrow subieron un 23,1% en el premercado. Descubre qué otras compañías están ganando y perdiendo antes de la apertura.

Las acciones de Harrow (HROW) se disparan un 23%; aquí están 20 acciones que se mueven en el premercado

Equities

Offerings

Small Cap

Acciones de Cel-Sci Corporation (CVM) caen tras anunciar oferta pública

CEL-SCI Corp

Morgan Stanley ETF Trust Calvert US Mid-Cap Core Responsible Index ETF

Sila Realty Trust Inc Ordinary Shares - Class A

Sila Realty Trust Inc Ordinary Shares - Class T

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) fell sharply in <a href="https://www.benzinga.com/quote/RARE">pre-market trading</a>.
Ultragenyx received a Complete Response Letter from the FDA for UX111 AAV gene therapy to treat Sanfilippo Syndrome Type A (MPS IIIA).
Ultragenyx Pharmaceutical shares dipped 8% to $27.15 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>MiNK Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) shares tumbled 31% to $44.25 in pre-market trading. MiNK Therapeutics shares jumped 730% on Friday after the company announced a publication in Oncogene.</li>
<li>Above Food Ingredients Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVE#NASDAQ">ABVE</a>) shares dipped 21.3% to $2.84 in pre-market trading after jumping 134% on Friday. Above Food Ingredients recently announced a merger agreement with Palm Global.</li>
<li>Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) declined 11.3% to $43.66 in pre-market trading after gaining 71% on Friday.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) shares dipped 11% to $3.08 in pre-market trading after declining 8% on Friday. CEL-SCI recently announced it signed a partnership with a Saudi Arabian pharma and healthcare company.</li>
<li>Unusual Machines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#NYSE">UMAC</a>) slipped 8% to $11.13 in pre-market trading after gaining 39% on Friday.</li>
<li>Gossamer Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) declined 6.6% to $1.2700 in pre-market trading. Gossamer Bio, last month, completed enrollment in its registrational Phase 3 PROSERA study for pulmonary arterial hypertension</li>
<li>Gilat Satellite Networks Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>) fell 4.1% to $7.22 in pre-market trading. Gilat Satellite Networks recently announced its commercial division received over $22 million in orders from satellite operators.</li>
<li>KalVista Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) dipped 4% to $13.94 in pre-market trading after falling 6% on Friday. KalVista Pharma recently posted a wider-than-expected quarterly loss.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) fell 1% to $209.22 in pre-market trading. Apple is in the midst of a significant management reshuffle. Despite the company's biggest crisis in years, CEO Tim Cook remains firmly at the helm.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46364472/top-3-real-estate-stocks-that-may-fall-off-a-cliff-this-month"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46364472/top-3-real-estate-stocks-that-may-fall-off-a-cliff-this-month">Top 3 Real Estate Stocks That May Fall Off A Cliff This Month</a></li>
</ul>
Photo via Shutterstock

AAPL

ABVE

GILT

GOSS

INKT

KALV

NEGG

RARE

UMAC

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Shares of Datavault AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVLT#NASDAQ">DVLT</a>) rose sharply in today's pre-market trading after the company entered into a licensing deal with IBM for <a href="https://www.benzinga.com/quote/DVLT">program subscriptions</a>.
Datavault AI shares jumped 7.1% to $0.7598 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>OceanPal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) climbed 120.4% to $3.00 in pre-market trading. On July 1, OceanPal regained compliance with Nasdaq Minimum Bid Price Requirement.</li>
<li>Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) surged 106% to $1.51 in pre-market trading after gaining 12% on Friday. Windtree Therapeutics recently announced it was issued an istaroxime patent for the United States for Acute Heart Failure.</li>
<li>Presidio Property Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQFT#NASDAQ">SQFT</a>) rose 59.9% to $8.17 in pre-market trading.</li>
<li>Stardust Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) jumped 39.2% to $0.3508 in pre-market trading after gaining 9% on Friday.</li>
<li>Rani Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) gained 39% to $0.8953 in pre-market trading. Rani Therapeutics announced that it will present preclinical data on the RaniPill&#xAE; capsule at the Endocrine Society&#8217;s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.</li>
<li>LQR House Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHC#NASDAQ">YHC</a>) gained 38.8% to $3.61 in pre-market trading after adding 31% on Friday.</li>
<li>BIT Mining Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCM#NASDAQ">BTCM</a>) gained 37.1% to $5.39 in pre-market trading after dipping 36% on Friday. BIT Mining recently announced it plans an investment up to $300 million to expand into the Solana ecosystem.</li>
<li>Sequans Communications S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) gained 16% to $5.26 in pre-market trading after gaining 15% on Friday. Sequans, last week, announced the launch of a bitcoin treasury program.</li>
<li>Aurora Mobile Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JG#NASDAQ">JG</a>) gained 15.8% to $13.55 in pre-market trading after the company highlighted its growth potential amid Bitcoin surge.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Everbright Digital Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDHL#NASDAQ">EDHL</a>) declined 60% to $1.72 in pre-market trading after dipping 25% on Friday.</li>
<li>MiNK Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) dipped 31% to $44.25 in pre-market trading. MiNK Therapeutics shares jumped 730% on Friday after the company announced a publication in Oncogene.</li>
<li>Future FinTech Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTFT#NASDAQ">FTFT</a>) dipped 27.6% to $2.85 in pre-market trading after gaining 160% on Friday.</li>
<li>Above Food Ingredients Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVE#NASDAQ">ABVE</a>) shares tumbled 21.3% to $2.84 in pre-market trading after jumping 134% on Friday. Above Food Ingredients recently announced a merger agreement with Palm Global.</li>
<li>Autozi Internet Technology (Global) Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) fell 20.2% to $0.2892 in pre-market trading after gaining 78% on Friday.</li>
<li>Boqii Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BQ#NYSE">BQ</a>) fell 16.2% to $3.63 in pre-market trading after gaining over 89% on Friday.</li>
<li>Signing Day Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>) declined 13.7% to $2.07 in pre-market trading. Signing Day Sports shares jumped 94% on Friday after the company announced it has made advancements regarding its business combination with One BlockchAIn</li>
<li>Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) fell 11.3% to $43.66 in pre-market trading after gaining 71% on Friday.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) shares fell 11% to $3.08 in pre-market trading after declining 8% on Friday. CEL-SCI recently announced it signed a partnership with a Saudi Arabian pharma and healthcare company.</li>
<li>Unusual Machines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#NYSE">UMAC</a>) fell 8% to $11.13 in pre-market trading after gaining 39% on Friday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46364472/top-3-real-estate-stocks-that-may-fall-off-a-cliff-this-month">Top 3 Real Estate Stocks That May Fall Off A Cliff This Month</a></li>
</ul>
Photo via Shutterstock

BTCM

DVLT

EDHL

FTFT

RANI

SDST

SQFT

SQNS

WINT

Why Datavault AI Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket

WIIM

CVM stock has given up its prior gain. CEL-SCI shares were trading higher after the company announced it signed a partnership with a Saudi Arabian pharma and healthcare company.

CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock is being sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $5.7 million. The offering is expected to close on July 14, 2025, subject to satisfaction of customary closing conditions.
The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital.
ThinkEquity is acting as the sole placement agent for the offering.

CEL-SCI Announces $5.7M Best-Efforts Offering Of 1.5M Shares At $3.82/Share; To Fund Cancer Immunotherapy Development

CEL-SCI shares are trading higher after the company announced it signed a partnership with a Saudi Arabian pharma and healthcare company.

Strong interest from Saudi investment funds in CEL-SCI, Multikine, and potential joint venture to address the wider Middle East and North Africa market
Patient access and reimbursement/sale in Saudi Arabia within approximately 60 days following filing for Breakthrough Medicine Designation
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54289130&amp;newsitemid=20250711051288&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=7741734321be9a8e482648858015c075">CEL-SCI Corporation</a> (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today announced it has reached an agreement with one of Saudi Arabia's premier pharmaceutical and healthcare companies for a partnership that spans regulatory and commercial activities for Multikine&#x2A; (Leukocyte Interleukin, Injection) in the Kingdom of Saudia Arabia. The formal agreement is expected to be signed with the Saudi pharmaceutical partner which will file a Breakthrough Medicine Designation application for Multikine with the Saudi Food and Drug Authority (SFDA) in the coming weeks. According to the SFDA, the response time to a Breakthrough Medicine Designation application is approximately 60 days. Following the granting of the Breakthrough Medicine Designation, Multikine would immediately become available for patient access and reimbursement/sale in Saudi Arabia. Several leading Saudi funds have expressed interest in investing in Multikine, CEL-SCI, and/or a potential joint venture to serve the wider Middle East and North Africa (MENA) market.
Multikine is an immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated head and neck cancer. In the world's largest head and neck cancer study spanning 20 countries, Multikine increased the 5-year survival rate of the target patient population to 73% vs 45% in patients treated with standard of care alone. The 5-year risk of death was halved from 55% to 27%.

CEL-SCI Signs Partnership Agreement With Saudi Arabian Pharma And Healthcare Company On Regulatory And Commercial Activities For Multikine In Kingdom Of Saudia Arabia

FDA priority review and approval based on interim results sets a positive precedent, paving the path for future Multikine approval
Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduced the risk of recurrence and progression (EFS) by 30% compared with standard of care in patients whose tumors expressed higher PD-L1 without demonstrating improvement in overall survival
Pre-operative treatments from CEL-SCI and Merck have the potential to offer clinical benefit for locally advanced resectable head and neck cancer patients across the PD-L1 expression spectrum
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54277978&amp;newsitemid=20250618276691&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=b70d9fa9d0281b85f045cc590edcf07d">CEL-SCI Corporation</a> (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today applauded the U.S. Food and Drug Administration's (FDA) <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fnews%2Ffda-approves-keytruda-pembrolizumab-for-pd-l1-resectable-locally-advanced-head-neck-squamous-cell-carcinoma-as-neoadjuvant-treatment-continued-as-adjuvant-treatment-combined-with-radiother%2F&amp;esheet=54277978&amp;newsitemid=20250618276691&amp;lan=en-US&amp;anchor=approval&amp;index=2&amp;md5=d0921aab7b73e58ab873719f9dc49400">approval</a> of Merck's KEYTRUDA&#xAE; (pembrolizumab), an anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test. Merck's application was granted the FDA's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fnews%2Ffda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-plus-standard-of-care-as-perioperative-treatment-for-resectable-locally-advanced-head-and-neck-squamous-cel%2F%23%3A%7E%3Atext%3DSearch%2520for%253A-%2CFDA%2520Grants%2520Priority%2520Review%2520to%2520Merck%27s%2520Application%2520for%2520KEYTRUDA%25C2%25AE%2Cand%2520Neck%2520Squamous%2520Cell%2520Carcinoma&amp;esheet=54277978&amp;newsitemid=20250618276691&amp;lan=en-US&amp;anchor=priority+review&amp;index=3&amp;md5=79fb8c0bc25f520e40a046b587c15102">priority review</a> on February 25, 2025, and regulatory approval was granted on June 13, 2025, based on interim results from Keytruda's Phase 3 <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03765918&amp;esheet=54277978&amp;newsitemid=20250618276691&amp;lan=en-US&amp;anchor=KEYNOTE-689&amp;index=4&amp;md5=361495621cb54f94ba824b3cb70c79cc">KEYNOTE-689</a> trial.
Last week the FDA approved Keytruda as a perioperative (before and after surgery) treatment for resectable locally advanced head and neck cancer patients whose tumors express PD-L1 at a positive level. In Merck's Phase 3 KEYNOTE-689 trial, Keytruda reduced the risk of recurrence and progression by 30%, compared with standard of care, in patients whose tumors expressed PD-L1 (CPS ≥1). The study did not show an improvement in overall survival. Patients with low to zero levels of PD-L1 did not benefit from Keytruda.
In contrast to the results of the KEYNOTE-689, CEL-SCI's Phase 3 study showed that Multikine&#x2A; treated patients whose tumors expressed low (Tumor Proportion Score [TPS &lt;10]) to zero PD-L1, had their risk of death reduced by 66% (hazard ratio 0.34, 95% CI [0.18, 0.65], p=0.0012) and extended the 5-year overall survival to 73% compared to 45% in the standard of care, log rank p=0.0015. About 70% of the patients in CEL-SCI's Phase 3 study had low to zero levels of PD-L1.

Biotech

General

CEL-SCI Highlights FDA Approval Of Merck's Keytruda As Precedent For Multikine, Citing 66% Reduction In Risk Of Death In Low/Zero PD-L1 Head And Neck Cancer Patients vs. Keytruda's 30% Recurrence Reduction In PD-L1 Positive Tumors

<h3>Gainers</h3>
<ul>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares moved upwards by 241.8% to $7.89 during Thursday's regular session. The company's market cap stands at $368.4 million. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) stock increased by 48.15% to $24.03. The market value of their outstanding shares is at $157.6 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock rose 32.85% to $1.86. The company's market cap stands at $5.3 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock rose 27.77% to $3.91. The market value of their outstanding shares is at $3.9 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) shares increased by 22.86% to $9.94. The company's market cap stands at $121.4 million. </li>
<li>Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) stock rose 21.24% to $1.85. The market value of their outstanding shares is at $132.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock fell 45.5% to $2.46 during Thursday's regular session. The company's market cap stands at $7.4 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares fell 31.29% to $1.28. The market value of their outstanding shares is at $24.1 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock fell 30.47% to $0.21. The company's market cap stands at $2.3 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 21.32% to $0.0. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock fell 21.04% to $0.3. The market value of their outstanding shares is at $2.3 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares declined by 15.01% to $0.01. As per the press release, Q1 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APVO

BMGL

EYEN

HCTI

PLRZ

VIGL

VTYX

12 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 0.2% on Thursday.
The Dow traded up 0.17% to 41,932.94 while the NASDAQ rose 0.66% to 18,997.89. The S&amp;P 500 also rose, gaining, 0.20% to 5,856.28.
Check This Out: <a href="https://www.benzinga.com/25/05/45563601/how-to-earn-500-a-month-from-intuit-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Intuit Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Communication services shares rose by 1.2% on Thursday.
In trading on Thursday, utilities stocks dipped by 1.9%.
Top Headline
U.S. initial jobless claims fell by 2,000 from the previous week to 227,000 in the week ending May 17, compared to market estimates of 230,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Vigil Neuroscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares shot up 242% to $7.91 after announcing Sanofi will acquire the company for approximately $600 million.</li>
<li>Shares of Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) got a boost, surging 130% to $4.3988 after NVIDIA selected the company to collaborate on 800 V HVDC architecture.</li>
<li>Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) shares were also up, gaining 46% to $45.61 following better-than-expected first-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) shares dropped 45% to $2.4887 following announcements for a $5 million public offering.</li>
<li>Shares of Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) were down 39% to $6.49. BMO Capital analyst Ameet Thakkar downgraded Sunrun from Market Perform to Underperform and lowered the price target from $9 to $4.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) was down, falling 19% to $38.25. Shares of solar companies tumbled as investors digested the consequences of President Donald Trump&#8217;s sweeping budget and tax package dubbed "One Big, Beautiful Bill.&#8221;</li>
</ul>
Commodities In commodity news, oil traded down 0.9% to $61.02 while gold traded down 0.3% at $3,302.90.
Silver traded down 1.5% to $33.13 on Thursday, while copper fell 0.3% to $4.660.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.89%, while Spain's IBEX 35 Index fell 0.56%. London's FTSE 100 dipped 0.85%, Germany's DAX 40 declined 0.69% and France's CAC 40 fell 0.95% during the session.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei falling 0.84%, Hong Kong's Hang Seng Index dipping 1.19%, China's Shanghai Composite Index falling 0.22% and India's BSE Sensex declining 0.79%.
Economics
<ul class="wp-block-list">
<li>U.S. existing home sales fell 0.5% month-over-month to an annual rate of 4.00 million in April, recording the lowest level in six months.</li>
<li>The S&amp;P Global services PMI climbed to 52.3 in May compared to 50.8 in the previous month.</li>
<li>The S&amp;P Global manufacturing PMI rose to 52.3 in May from 50.2 in April.</li>
<li>The Chicago Fed National Activity Index dipped to -0.25 in April compared to a revised reading of +0.03 in March.</li>
<li>U.S. initial jobless claims fell by 2,000 from the previous week to 227,000 in the week ending May 17, compared to market estimates of 230,000.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45564349/accenture-to-rally-more-than-24-here-are-10-top-analyst-forecasts-for-thursday">Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Commodities

Intraday Update

ENPH

Dow Moves Higher; US Initial Jobless Claims Fall

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday.
Following the market opening Thursday, the Dow traded up 0.01% to 41,866.30 while the NASDAQ rose 0.74% to 19,011.97. The S&amp;P 500 also rose, gaining, 0.20% to 5,856.20.
Check This Out: <a href="https://www.benzinga.com/25/05/45563601/how-to-earn-500-a-month-from-intuit-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Intuit Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Communication services shares rose by 1.7% on Thursday.
In trading on Thursday, utilities stocks dipped by 1.8%.
Top Headline
BJ's Wholesale Club Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) posted better-than-expected earnings for its first quarter on Thursday.
The company registered adjusted earnings per share of $1.14, beating the analyst consensus estimate of 92 cents. Quarterly revenues of $5.15 billion (+4.7% year over year) missed the Street view of $5.20 billion.
BJ's Wholesale Club has reaffirmed its full-year 2025 adjusted earnings guidance of $4.10 to $4.30 per share, compared with the $4.24 estimate.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Vigil Neuroscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares shot up 243% to $7.91 after announcing Sanofi will acquire the company for approximately $600 million.</li>
<li>Shares of Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) got a boost, surging 128% to $4.3335 after NVIDIA selected the company to collaborate on 800 V HVDC architecture.</li>
<li>Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) shares were also up, gaining 44% to $45.14 following better-than-expected first-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) shares dropped 46% to $2.4309 following announcements for a $5 million public offering.</li>
<li>Shares of Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) were down 40% to $6.44. BMO Capital analyst Ameet Thakkar downgraded Sunrun from Market Perform to Underperform and lowered the price target from $9 to $4.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) was down, falling 16% to $39.85.</li>
</ul>
Commodities In commodity news, oil traded down 1.6% to $60.57 while gold traded down 0.6% at $3,294.10.
Silver traded down 1.8% to $33.04 on Thursday, while copper fell 0.7% to $4.6410.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.1%, while Spain's IBEX 35 Index fell 0.7%. London's FTSE 100 dipped 1%, Germany's DAX 40 declined 0.9% and France's CAC 40 fell 1.1% during the session.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei falling 0.84%, Hong Kong's Hang Seng Index dipping 1.19%, China's Shanghai Composite Index falling 0.22% and India's BSE Sensex declining 0.79%.
Economics
<ul class="wp-block-list">
<li>U.S. existing home sales fell 0.5% month-over-month to an annual rate of 4.00 million in April, recording the lowest level in six months.</li>
<li>The S&amp;P Global services PMI climbed to 52.3 in May compared to 50.8 in the previous month.</li>
<li>The S&amp;P Global manufacturing PMI rose to 52.3 in May from 50.2 in April.</li>
<li>The Chicago Fed National Activity Index dipped to -0.25 in April compared to a revised reading of +0.03 in March.</li>
<li>U.S. initial jobless claims fell by 2,000 from the previous week to 227,000 in the week ending May 17, compared to market estimates of 230,000.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45564349/accenture-to-rally-more-than-24-here-are-10-top-analyst-forecasts-for-thursday">Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday</a> </li>
</ul>
Photo via Shutterstock

Nasdaq Gains Over 100 Points; BJ's Wholesale Earnings Top Views

CEL-SCI shares are trading lower following announcements for a $5 million public offering.

<h3>Gainers</h3>
<ul>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) stock increased by 243.7% to $7.94 during Thursday's pre-market session. The market value of their outstanding shares is at $370.5 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares moved upwards by 62.41% to $4.97. The market value of their outstanding shares is at $4.9 million. </li>
<li>Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) shares increased by 13.01% to $1.73. The market value of their outstanding shares is at $123.0 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares rose 12.79% to $25.75. The company's market cap stands at $155.0 million. </li>
<li>HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) stock increased by 11.84% to $1.7. The market value of their outstanding shares is at $20.7 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock increased by 10.57% to $4.81. The market value of their outstanding shares is at $2.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) shares fell 47.5% to $2.37 during Thursday's pre-market session. The company's market cap stands at $7.1 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock fell 17.55% to $0.25. The company's market cap stands at $2.7 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares fell 8.8% to $52.9. The company's market cap stands at $11.8 billion. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares decreased by 8.66% to $0.36. The company's market cap stands at $52.8 million. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) stock decreased by 7.49% to $0.81. The company's market cap stands at $15.8 million. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock decreased by 7.49% to $3.09. The market value of their outstanding shares is at $33.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDSX

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HOOK

HSDT

LTRN

MTVA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Shares of Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) rose sharply in today's pre-market following better-than-expected <a href="https://in.benzinga.com/markets/equities/25/05/45559366/urban-outfitters-navigates-tariff-headwinds-with-diversification-strategies-no-country-accounts-for-more-than-25-of-production">first-quarter financial results.</a>
Urban Outfitters reported quarterly earnings of $1.16 per share, which beat the analyst consensus estimate of 82 cents. Quarterly revenue clocked in at $1.33 billion, which beat the Street estimate of $1.28 billion.
Urban Outfitters shares jumped 18% to $70.32 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) rose 172.2% to $5.20 in pre-market trading after NVIDIA selected the company to collaborate on 800 V HVDC architecture.</li>
<li>Longevity Health Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) surged 60.1% to $4.87 in pre-market trading after the company announced it will retain its Nasdaq listing to complete its merger with 20/20 Biolabs.</li>
<li>AtlasClear Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NYSE">ATCH</a>) jumped 23.2% to $0.2487 in pre-market trading after falling 11% on Wednesday.</li>
<li>Bit Origin Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) gained 20.9% to $0.1920 in pre-market trading after declining 9% on Wednesday.</li>
<li>Nine Energy Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) surged 19.7% to $0.6057 in pre-market trading after falling 10% on Wednesday.</li>
<li>Kindly MD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) gained 16.9% to $26.69 in pre-market trading. Nakamoto Holdings, Kindly MD, and Anchorage Digital disclosed a strategic partnership to advance the future of corporate Bitcoin adoption.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) climbed 14.6% to $4.37 in pre-market trading after the company announced the sale of its consumer fiber-to-the-home business to AT&amp;T for $5.75 billion in cash.</li>
<li>Pitney Bowes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) gained 11.4% to $10.14 in pre-market trading after the company reported better-than-expected first-quarter adjusted EPS results.</li>
<li>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) rose 10.3% to $197.52 in pre-market trading after the company posted better-than-expected earnings and sales results for the first quarter. The company also said it expects second-quarter product revenue in the range of $1.035 billion to $1.04 billion, up approximately 25% year-over-year. The company anticipates full-year product revenue of $4.33 billion, representing 25% year-over-year growth.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) shares fell 43.7% to $2.54 in pre-market trading after the company reported the pricing of public offering.</li>
<li>Catheter Precision, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NYSE">VTAK</a>) fell 18.8% to $0.2450 in pre-market trading. Catheter Precision filed for resale of up to 12.9 million shares of common stock by the selling stockholders.</li>
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) fell 16.1% to $0.89 in today's pre-market trading after announcing a 1-for-7 reverse stock split.</li>
<li>Lottery.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRY#NASDAQ">LTRY</a>) shares dipped 15.2% to $1.51 in pre-market trading. Lottery.com shares jumped 135% on Wednesday after the company reported a year-over-year increase in first-quarter EPS results.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares tumbled 15.1% to $9.05 in pre-market trading after declining around 8% on Wednesday.</li>
<li>Digital Ally, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) fell 13.7% to $0.0259 in pre-market trading. Digital Ally shares fell around 17% on Wednesday after the company reported a year-over-year decrease in first-quarter sales results.</li>
<li>Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) dipped 13.6% to $0.1450 in pre-market trading after tumbling 10% on Wednesday.</li>
<li>Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) declined 9.5% to $11.56 in pre-market trading after gaining over 29% on Wednesday.</li>
<li>Manchester United plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) shares fell 6.9% to $13.54 in pre-market trading.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) fell 5.2% to $18.81 in pre-market trading. GLJ Research analyst Gordon Johnson, on Wednesday, maintained SolarEdge with a Sell and raised the price target from $3.9 to $6.9.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/25/05/45540545/jim-cramer-recommends-not-buying-mosaic-doesnt-like-this-industrial-stock">Jim Cramer Recommends Not Buying Mosaic, Doesn&#8217;t Like This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Why Urban Outfitters Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

Reported Earlier, CEL-SCI Prices $5M Public Offering At $2.50/Share To Advance Multikine Cancer Immunotherapy Development

<h3>Gainers</h3>
<ul>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares moved upwards by 55.5% to $4.76 during Wednesday's after-market session. The market value of their outstanding shares is at $4.7 million. </li>
<li>SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) shares moved upwards by 15.94% to $2.0. The market value of their outstanding shares is at $18.5 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) stock rose 9.3% to $0.53. The market value of their outstanding shares is at $6.0 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares rose 7.26% to $3.1. The company's market cap stands at $13.8 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock moved upwards by 7.2% to $1.99. The market value of their outstanding shares is at $2.9 million. </li>
<li>Immutep (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) stock moved upwards by 6.7% to $2.07. The market value of their outstanding shares is at $301.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares decreased by 37.0% to $0.04 during Wednesday's after-market session. As per the news, the Q1 earnings report came out 4 days ago. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock declined by 20.4% to $3.59. The company's market cap stands at $326.8 million. The company's, Q2 earnings came out 4 days ago. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares decreased by 12.72% to $1.03. The market value of their outstanding shares is at $5.8 million. As per the news, the Q1 earnings report came out 4 days ago. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock fell 12.26% to $0.27. The company's market cap stands at $2.9 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock decreased by 7.02% to $0.36. The market value of their outstanding shares is at $21.0 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares decreased by 6.76% to $0.37. The market value of their outstanding shares is at $53.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

BCAB

BCLI

BJDX

IMMP

LIPO

PTPI

SABS

12 Health Care Stocks Moving In Wednesday's After-Market Session

CEL-SCI shares are trading lower after the company announced a proposed public offering.

CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>), a clinical stage cancer immunotherapy company,today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) in an underwritten public offering. All of the shares of common stock (and/or Pre-Funded Warrants) are being offered by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The Company intends to use the net proceeds from this offering to fund the continued development of Multikine&#x2A;, for general corporate purposes, and working capital.
ThinkEquity is acting as sole book-running manager for the offering.

CEL-SCI Announces Proposed Public Offering; No Size Or Amount Disclosed

CEL-SCI Completes Breakthrough Medicine Designation Application For Multikine For Submission To Saudi Food And Drug Authority

<h3>Gainers</h3>
<ul>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 39.5% to $0.38 during Tuesday's after-market session. The company's market cap stands at $55.3 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock rose 26.37% to $0.16. The company's, Q1 earnings came out 3 days ago. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) stock rose 15.6% to $0.81. The market value of their outstanding shares is at $8.2 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock rose 9.8% to $5.61. The market value of their outstanding shares is at $510.8 million. The company's, Q2 earnings came out 3 days ago. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock rose 7.23% to $0.44. The market value of their outstanding shares is at $12.1 million. </li>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) stock increased by 6.7% to $0.52. The market value of their outstanding shares is at $53.9 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 9.0% to $5.49 during Tuesday's after-market session. The market value of their outstanding shares is at $83.5 million. </li>
<li>HeartSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares declined by 6.46% to $4.2. The company's market cap stands at $4.5 million. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock fell 6.21% to $11.18. The company's market cap stands at $206.7 million. </li>
<li>HilleVax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) stock declined by 5.95% to $1.9. The company's market cap stands at $95.1 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares decreased by 5.94% to $0.39. The company's market cap stands at $7.1 million. </li>
<li>Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) stock decreased by 5.77% to $0.66. The market value of their outstanding shares is at $92.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HLVX

HSCS

INTS

ONMD

OPRX

VNRX

XTNT

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock moved upwards by 2412.3% to $5.12 during Tuesday's regular session. The company's market cap stands at $466.1 million. The company's, Q2 earnings came out 3 days ago. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock increased by 42.47% to $1.61. The company's market cap stands at $4.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock moved upwards by 23.28% to $0.28. The company's market cap stands at $5.0 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 22.5% to $431.22. The market value of their outstanding shares is at $5.6 billion. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) stock rose 18.79% to $1.68. The market value of their outstanding shares is at $307.3 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares increased by 17.2% to $1.35. The company's market cap stands at $53.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock fell 31.1% to $7.65 during Tuesday's regular session. The market value of their outstanding shares is at $4.5 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares decreased by 17.74% to $8.88. The company's market cap stands at $243.0 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) shares fell 15.14% to $0.28. The company's market cap stands at $8.1 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares decreased by 13.64% to $0.01. </li>
<li>Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) shares declined by 12.62% to $7.38. The company's market cap stands at $629.6 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 11.85% to $5.25. The company's market cap stands at $285.3 million. The company's, Q1 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALMS

AVXL

BIAF

DBVT

EKSO

PTIX

TELA

12 Health Care Stocks Moving In Tuesday's Intraday Session

Press Releases

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

CEL-SCI Announces Combination of Common Stock

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

CEL-SCI Announces Proposed Public Offering

CEL-SCI Announces Pricing of Public Offering

CEL-SCI Announces Closing of Public Offering

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

Comments

CEL-SCI

Noticias

Últimas noticias sobre CEL-SCI (AMEX:CVM) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL